NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies

FT538

induced pluripotent stem cell-derived CD16/IL-15RF-expressing CD38-eliminated natural killer cells FT538

NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies

This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Sponsor

Fate Therapeutics

---

ClinicalTrials.gov Identifier: NCT04614636

Official Title: A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma

First Posted : November 4, 2020

Click here for details on ClinicalTrials.gov

---

FT 538

iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 (Code C176623)

FT 538

FT-538

FT538

induced pluripotent stem cell-derived CD16/IL-15RF-expressing CD38-eliminated natural killer cells FT538

---

Drug: FT538

Drug: Cyclophosphamid

Drug: Fludarabine

Drug: Daratumumab

Drug: Elotuzumab

---

- Multiple locations

- New York: Memorial Sloan-Kettering Cancer Center New York

- Tennessee: Sarah Cannon Research Institute Nashville

- Missouri: Washington University School of Medicine Saint Louis

- Texas: The University of Texas MD Anderson Cancer Center Houston

---

Locations

United States, Colorado

United States, Minnesota

United States, Missouri

United States, New Jersey

United States, New York

United States, Tennessee

United States, Texas